Arda Therapeutics, a San Francisco, CA-based company which specializes in targeted cell depletion therapies for chronic diseases, raised $43M in Series A funding.
The round was led by Andreessen Horowitz (a16z Bio + Health), with participation from Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV, Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels and ExitFund.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Adam Freund, Arda Therapeutics is improving the use of targeted cell depletion to treat chronic diseases. By identifying and selectively depleting pathogenic cells, it aims to develop therapies that offer efficacy, discovery timelines and reduced dosing frequency compared to traditional approaches.
Its platform has broad applicability across a wide range of diseases, including fibrotic conditions such as pulmonary fibrosis, as well as autoimmune and metabolic disorders.
In addition to the financing, Arda announced the appointment of Scott Turner, Ph.D., as chief scientific officer.
